[Thymalin in the combined treatment of patients with chronic lympholeukemia].
Babenko. T F TF; Antonenko. V T VT; SkuratovskiUi. M F MF
Key Findings
- Thymalin improved functional activity of lymphoid cells in CLL patients
- Time to clinico‑hematological remission was reduced with thymalin
- Authors suggest thymalin as part of combination therapy for this condition
Practical Outcomes
- The data hint that thymalin could support immune recovery in chronic leukemia, but the study is small and lacks dosing details. Biohackers should treat this as preliminary evidence and only consider use under professional medical guidance, not as a standalone protocol.
Summary
Adding the peptide thymalin to standard treatment for a type of chronic leukemia (B‑variant CLL, stage II) seemed to boost immune cell activity and helped patients reach remission faster, according to the study.
Abstract
Clinico-immunologic indices were studied in patients with the B-variant of chronic lympholeukemia (Stage II) under conditions of inclusion of thymalin in the complex treatment. It was established that use of thymalin in patients with chronic lympholeukemia favoured improvement of the functional activity of lymphoid cells, reduced the time of reaching clinico-hematological remission. Thymalin is indicated in the complex treatment of the above condition.
Study Information
pubmed
1989